| Name | H-89 |
| Description | H-89 is a selective and potent protein kinase A inhibitor (IC50: 48 nM), a candidate cardioprotectant, induces spatial learning impairment in rats, and can be used to study myocardial infarction. |
| In vitro | Pretreatment of PC12D cells with H-89 (30 μM) significantly inhibited cAMP-dependent histone IIb phosphorylation activity in cell lysates, but did not affect other protein phosphorylation activities [1]; in rat skin EDL fibers , H-89 (10 μM) only slightly inhibited the force response to depolarization; H-89 (1-2 μM) significantly slowed the re-excitation rate in rat skin EDL fibers, most likely because of its Deleteriously affects the T system potential; H-89 (10-100 μM) also inhibits the net uptake of Ca2+ by SR. [2] |
| In vivo | b>METHODS: H-89 (0.05, 0.1, 0.2 mg/100 g, intraperitoneal injection) was used 30 minutes before the infusion of pentylene tetrazolium (PTZ) in mice to study the effect of H-89 on Bucladesine-induced epileptic activity in PTZ-treated mice.
RESULTS: H-89 (0.2 mg/100 g) significantly increased the seizure latency and threshold of PTZ-treated animals; H-89 (0.05, 0.2 mg/100 g) blocked the epileptogenic activity of Bucladesine and significantly increased the seizure latency and seizure threshold. [3] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (134.42 mM), Sonication is recommended.
|
| Keywords | Protein kinase inhibitor H-89 | H-89 |
| Inhibitors Related | Daphnetin | Capivasertib | GSK180736A | Ellagic acid | Fasudil | Acefylline | Ro-3306 | Metadoxine | Staurosporine | 8-Bromo-cAMP sodium salt | Fasudil hydrochloride | JAK1/2/3 Inhibitor 1 |
| Related Compound Libraries | 经典已知活性库 | 酪氨酸激酶分子库 | 激酶抑制剂库 | 抑制剂库 | 抗心血管疾病化合物库 | 已知活性化合物库 |
United States
